Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revision Both sides next revision | ||
|
covid:unpublished [2020/07/02 16:14] biogridadmin |
covid:unpublished [2020/08/05 13:14] biogridadmin |
||
|---|---|---|---|
| Line 38: | Line 38: | ||
| | **888800000033** | **[[https://doi.org/10.1101/2020.05.01.20077743|10.1101/2020.05.01.20077743]]** | Wu Y (2020) | **[[https://thebiogrid.org/221836/publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** | | | **888800000033** | **[[https://doi.org/10.1101/2020.05.01.20077743|10.1101/2020.05.01.20077743]]** | Wu Y (2020) | **[[https://thebiogrid.org/221836/publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** | | ||
| | **888800000034** | **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]** | Liu X (2020) | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** | | | **888800000034** | **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]** | Liu X (2020) | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** | | ||
| + | |||
| + | ^ Custom ID ^ DOI ^ AUTHOR ^ DATASET ^ | ||
| + | | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | ||
| + | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | ||
| + | | **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | ||
| + | | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | ||
| + | | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | ||
| + | | **888800000007** | **[[https://doi.org/10.1101/2020.02.26.964882|10.1101/2020.02.26.964882]]** | Jin Z (2020) | **[[https://thebiogrid.org/221186/publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]** | | ||
| + | | **888800000008** | **[[https://doi.org/10.1101/2020.03.29.013490|10.1101/2020.03.29.013490]]** | Wang C (2020) | **[[https://thebiogrid.org/221195/publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** | | ||
| + | | **888800000009** | **[[https://doi.org/10.1101/2020.03.25.996348|10.1101/2020.03.25.996348]]** | Dai W (2020) | **[[https://thebiogrid.org/221196/publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** | | ||
| + | | **888800000010** | **[[https://doi.org/10.1101/2020.03.15.992883|10.1101/2020.03.15.992883]]** | Joyce MG (2020) | **[[https://thebiogrid.org/221197/publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]** | | ||
| + | | **888800000011** | **[[https://doi.org/10.1101/2020.03.16.993386|10.1101/2020.03.16.993386]]** | Gao Y (2020) | **[[https://thebiogrid.org/221198/publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]** | | ||
| + | | **888800000012** | **[[https://doi.org/10.1101/2020.03.31.019216|10.1101/2020.03.31.019216]]** | Liang Q (2020) | **[[https://thebiogrid.org/221199/publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** | | ||
| + | | **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | ||
| + | | **888800000016** | **[[https://doi.org/10.1101/2020.04.14.042010|10.1101/2020.04.14.042010]]** | Chi X (2020) | **[[https://thebiogrid.org/221405/publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** | | ||
| + | | **888800000017** | **[[https://doi.org/10.1101/2020.04.06.20055475|10.1101/2020.04.06.20055475]]** | Ye L (2020) | **[[https://thebiogrid.org/221565/publication|Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor]]** | | ||
| + | | **888800000018** | **[[https://doi.org/10.1101/2020.04.19.049643|10.1101/2020.04.19.049643]]** | Zeng X (2020) | **[[https://thebiogrid.org/221566/publication|Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy]]** | | ||
| + | | **888800000019** | **[[https://doi.org/10.1101/2020.04.23.057265|10.1101/2020.04.23.057265]]** | Peng Q (2020) | **[[https://thebiogrid.org/221567/publication|Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus]]** | | ||
| + | | **888800000020** | **[[https://doi.org/10.1101/2020.04.22.046565|10.1101/2020.04.22.046565]]** | Liu Y (2020) | **[[https://thebiogrid.org/221568/publication|Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2]]** | | ||
| + | | **888800000021** | **[[https://doi.org/10.1101/2020.04.21.053017|10.1101/2020.04.21.053017]]** | Walker A (2020) | **[[https://thebiogrid.org/221569/publication|Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases]]** | | ||
| + | | **888800000022** | **[[https://doi.org/10.1101/2020.04.17.047498|10.1101/2020.04.17.047498]]** | Rosas Lemus M (2020) | **[[https://thebiogrid.org/221570/publication|The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine]]** | | ||
| + | | **888800000023** | **[[https://doi.org/10.1101/2020.04.19.048710|10.1101/2020.04.19.048710]]** | Zhao X (2020) | **[[https://thebiogrid.org/221571/publication|Broad and differential animal ACE2 receptor usage by SARS-CoV-2]]** | | ||
| + | | **888800000024** | **[[https://doi.org/10.1101/2020.04.26.061705|10.1101/2020.04.26.061705]]** | Viswanathan T (2020) | **[[https://thebiogrid.org/221642/publication|Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus]]** | | ||
| + | | **888800000025** | **[[https://doi.org/10.1101/2020.04.29.068890|10.1101/2020.04.29.068890]]** | Rut W (2020) | **[[https://thebiogrid.org/221777/publication|Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design]]** | | ||
| + | | **888800000026** | **[[https://doi.org/10.1101/2020.04.27.063180|10.1101/2020.04.27.063180]]** | Hillen HS (2020) | **[[https://thebiogrid.org/221778/publication|Structure of replicating SARS-CoV-2 polymerase]]** | | ||
| + | | **888800000027** | **[[https://doi.org/10.1101/2020.04.29.068098|10.1101/2020.04.29.068098]]** | Sun Z (2020) | **[[https://thebiogrid.org/221779/publication|Mass spectrometry analysis of newly emerging coronavirus HCoV-19 spike S protein and human ACE2 reveals camouflaging glycans and unique post-translational modifications]]** | | ||
| + | | **888800000028** | **[[https://doi.org/10.1101/2020.05.03.073080|10.1101/2020.05.03.073080]]** | Vuong W (2020) | **[[https://thebiogrid.org/221830/publication|Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication]]** | | ||
| + | | **888800000029** | **[[https://doi.org/10.1101/2020.05.02.20086876|10.1101/2020.05.02.20086876]]** | Zhang D (2020) | **[[https://thebiogrid.org/221831/publication|Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)]]** | | ||
| + | | **888800000030** | **[[https://doi.org/10.1101/2020.05.05.079202|10.1101/2020.05.05.079202]]** | Huo J (2020) | **[[https://thebiogrid.org/221832/publication|Neutralization of SARS-CoV-2 by destruction of the prefusion Spike]]** | | ||
| + | | **888800000031** | **[[https://doi.org/10.1101/2020.05.06.079830|10.1101/2020.05.06.079830]]** | Zha L (2020) | **[[https://thebiogrid.org/221833/publication|Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles]]** | | ||
| + | | **888800000032** | **[[https://doi.org/10.1101/2020.05.02.043554|10.1101/2020.05.02.043554]]** | Gunther S (2020) | **[[https://thebiogrid.org/221835/publication|Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease]]** | | ||
| + | | **888800000033** | **[[https://doi.org/10.1101/2020.05.01.20077743|10.1101/2020.05.01.20077743]]** | Wu Y (2020) | **[[https://thebiogrid.org/221836/publication|A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2]]** | | ||
| + | | **888800000034** | **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]** | Liu X (2020) | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** | | ||
| + | | **888800000035** | **[[https://doi.org/10.1101/2020.05.21.109157|10.1101/2020.05.21.109157]]** | Lui I (2020) | **[[https://thebiogrid.org/222215/publication|Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]** | | ||
| + | | **888800000036** | **[[https://doi.org/10.1101/2020.05.21.107870|10.1101/2020.05.21.107870]]** | Partridge LJ (2020) | **[[https://thebiogrid.org/222216/publication|Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line]]** | | ||
| + | | **888800000037** | **[[https://doi.org/10.1101/2020.05.13.092478|10.1101/2020.05.13.092478]]** | Chiodo F (2020) | **[[https://thebiogrid.org/222217/publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]** | | ||
| + | | **888800000038** | **[[https://doi.org/10.1101/2020.05.12.091298|10.1101/2020.05.12.091298]]** | Seydoux E (2020) | **[[https://thebiogrid.org/222218/publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]** | | ||
| + | | **888800000039** | **[[https://doi.org/10.1101/2020.05.21.107565|10.1101/2020.05.21.107565]]** | Zang J (2020) | **[[https://thebiogrid.org/222219/publication|Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement]]** | | ||
| + | | **888800000040** | **[[https://doi.org/10.1101/2020.05.12.092171|10.1101/2020.05.12.092171]]** | Zhou X (2020) | **[[https://thebiogrid.org/222220/publication|Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation]]** | | ||
| + | | **888800000041** | **[[https://doi.org/10.1101/2020.06.17.156455|10.1101/2020.06.17.156455]]** | Stukalov A (2020) | **[[https://thebiogrid.org/222410/publication|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]** | | ||
| + | | **888800000042** | **[[https://doi.org/10.1101/2020.06.05.135921|10.1101/2020.06.05.135921]]** | Bertoglio F (2020) | **[[https://thebiogrid.org/222602/publication|SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface]]** | | ||
| + | | **888800000043** | **[[https://doi.org/10.1101/2020.06.05.135699|10.1101/2020.06.05.135699]]** | Moustaqil M (2020) | **[[https://thebiogrid.org/222603/publication|SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]** | | ||
| + | | **888800000044** | **[[https://doi.org/10.1101/2020.06.17.157982|10.1101/2020.06.17.157982]]** | Starr TN (2020) | **[[https://thebiogrid.org/222652/publication|Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding]]** | | ||
| + | | **888800000045** | **[[https://doi.org/10.1101/2020.06.05.134114|10.1101/2020.06.05.134114]]** | Daly JL (2020) | **[[https://thebiogrid.org/222653/publication|Neuropilin-1 is a host factor for SARS-CoV-2 infection]]** | | ||
| + | | **888800000046** | **[[https://doi.org/10.1101/2020.06.17.158121|10.1101/2020.06.17.158121]]** | Cubuk J (2020) | **[[https://thebiogrid.org/222654/publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** | | ||
| + | | **888800000047** | **[[https://doi.org/10.1101/2020.06.09.142794|10.1101/2020.06.09.142794]]** | Yang Y (2020) | **[[https://thebiogrid.org/222655/publication|The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.]]** | | ||
| + | | **888800000048** | **[[https://doi.org/10.1101/2020.06.02.130161|10.1101/2020.06.02.130161]]** | Hanke L (2020) | **[[https://thebiogrid.org/222656/publication|An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction]]** | | ||
| + | | **888800000049** | **[[https://doi.org/10.1101/2020.06.17.156471|10.1101/2020.06.17.156471]]** | Conceicao C (2020) | **[[https://thebiogrid.org/222704/publication|The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins]]** | | ||
| + | | **888800000050** | **[[https://doi.org/10.1101/2020.06.07.138677|10.1101/2020.06.07.138677]]** | Luan X (2020) | **[[https://thebiogrid.org/222705/publication|Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]** | | ||
| + | | **888800000051** | **[[https://doi.org/10.1101/2020.06.02.129098|10.1101/2020.06.02.129098]]** | Lv Z (2020) | **[[https://thebiogrid.org/222706/publication|Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody]]** | | ||
| + | | **888800000052** | **[[https://doi.org/10.1101/2020.06.06.137513|10.1101/2020.06.06.137513]]** | Lou Y (2020) | **[[https://thebiogrid.org/222707/publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]** | | ||
| + | | **888800000053** | **[[https://doi.org/10.1101/2020.05.27.118117|10.1101/2020.05.27.118117]]** | Douangamath A (2020) | **[[https://thebiogrid.org/222708/publication|Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease]]** | | ||
| + | | **888800000054** | **[[https://doi.org/10.1101/2020.06.16.155812|10.1101/2020.06.16.155812]]** | Li J (2020) | **[[https://thebiogrid.org/222709/publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]** | | ||
| + | | **888800000055** | **[[https://doi.org/10.1101/2020.06.15.153387|10.1101/2020.06.15.153387]]** | Beddingfield B (2020) | **[[https://thebiogrid.org/222710/publication|The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection]]** | | ||